Italia markets open in 6 hours 15 minutes

Illumina, Inc. (ILMN)

NasdaqGS - NasdaqGS Prezzo in tempo reale. Valuta in USD.
Aggiungi a portafoglio
305,50+0,04 (+0,01%)
Alla chiusura: 4:00PM EDT

305,50 0,00 (0,00%)
Dopo ore: 6:53PM EDT

Accedi per pubblicare un messaggio.
  • s
    stocktargetadvisor
    $ILMN conversation
    $ILMN
    Target Lowered by Robert W Baird Neutral USD 335 » USD 281
    Target Lowered by SVB Leerink Outperform USD 360 » USD 315
    Downgraded by UBS Buy » Neutral USD 390 » USD 285
    Downgraded by Stifel Nicolaus Buy » Hold USD 380 » USD 280
  • s
    stocktargetadvisor
    $ILMN conversation
    $ILMN
    Downgraded by Stifel Nicolaus Buy » Hold USD 380 » USD 280
    Downgraded by UBS Buy » Neutral USD 390 » USD 285
    Target Lowered by SVB Leerink Outperform USD 360 » USD 315
    Target Lowered by Robert W Baird Neutral USD 335 » USD 281
  • D
    Denis
    $ILMN conversation
    ILMN stock and AYX stock BUY THE DIP situation📈, TSLA stock trade results
    www.youtube.com
  • s
    stocktargetadvisor
    $ILMN conversation
    $ILMN
    Initiates Coverage On Morgan Stanley Equal-Weight USD 400
  • S
    Stocktargetadvisor
    $ILMN conversation
    $ILMN
    Target Lowered by SVB Leerink Outperform USD 370 » USD 360
    Downgraded by Piper Sandler Overweight » Neutral USD 356 » USD 340
    Downgraded by Evercore ISI In-Line » Underperform USD 310
    Downgraded by Guggenheim Securities Buy » Neutral
  • S
    Stocktargetadvisor
    $ILMN conversation
    $ILMN
    Target Lowered by SVB Leerink Outperform USD 370 » USD 360
    Downgraded by Piper Sandler Overweight » Neutral USD 356 » USD 340
    Downgraded by Evercore ISI In-Line » Underperform USD 310
  • b
    bear hunter
    $PACB conversation
    Monster moves from the $ILMN acquisition news, but keep in mind that $PACB shareholders have the final say. What's everyone's thoughts? https://medium.com/@stockmarketdiva/3-healthcare-stocks-hitting-fresh-highs-4bae339d5f95
    The healthcare sector is often regarded as a hedge from regular market forces. Recent volatility has brought this particular topic to…
    The healthcare sector is often regarded as a hedge from regular market forces. Recent volatility has brought this particular topic to…
    medium.com
  • Z
    Zeev
    Inovio Pharmaceuticals, Inc.
    Don't forget that Jim Cramer did not believe in success of Tesla till Tesla has proven him wrong. Later he admitted that he was wrong and even apologised for his followers about missing the opportunity with Tesla on their early stage.
    He is not really capable recognizing distruptive technolodies and distruptive companies. That is not his strong side. He is an old school man.
    Not alike Cateherine from Ark Invest. She is just hunting distruptive technologies of tomorrow and dustruptive companies like $TSLA with their battery technologies and authonomus driving, like $ILMN, like $INO with their DNA vaccines against Cancer and with their revolutionary Celectra delivery divice the only one in the market capable to deliver these DNA vaccines directly into the cells. By the way - Ark Invest is heavily invested in $INO.

    Jim Cramer will realise that Inovio is not only speculative stock only when Inovio will become profitable. That is when he realised about Tesla.

    https://www.cnbc.com/2020/04/21/jim-cramer-millennials-are-investing-in-these-good-speculative-stocks.html

    https://www.nasdaq.com/market-activity/stocks/ino/institutional-holdings
    Robinhood trading app's top 10 stock picks for March is a "fantastic list" for younger investors, the "Mad Money" host said.
    Robinhood trading app's top 10 stock picks for March is a "fantastic list" for younger investors, the "Mad Money" host said.
    www.cnbc.com
  • M
    Mike
    Pacific Biosciences of California, Inc.
    Pacific Biosciences Inching Closer To A Key Event https://seekingalpha.com/article/4205968?source=ansh $PACB, $ILMN
    PacBio continues to grind through a challenging period as customers delay instrument purchases and consumables revenue shifts away from legacy systems. The ZMW
    PacBio continues to grind through a challenging period as customers delay instrument purchases and consumables revenue shifts away from legacy systems. The ZMW
    seekingalpha.com
  • D
    Dimi
    $BNGO conversation
    $BNGO biotech traders are either asleep or don't bother to read SEC filings..welcome to the next $ILMN $BPTH.
  • M
    Michael
    $ILMN conversation
    This will be the 4th time this stock has tumbled to the 130-140 in the last 18months. If it holds, $130, and it likely will, buy every share that you can afford. When Grail hits a home run, and when 23&me goes public---this stock will soar to the $400 to $500 range. This stock will recover.
  • K
    Kirkydu
    $EXAS conversation
    The Illumina $ILMN speculation is more likely to do with a partnership, licensing or development deal than a buyout. Folks need to remember that $EXAS had a high in the low $30s and secondary offerings in the middle $20s. It is very unlikely we see a buyout below those levels. Also, consider that Exact has plenty of cash on the balance sheets, growing sales and a POISON PIll that essentially makes a hostile takeover about 4x more expensive than prevailing stock price. So, while a takeover will likely happen someday in order to completely develop the pipeline - I'd speculate 2018-19 if it happens at all - for now, consider that Exact's liquid biopsy technology might be of interest to a big player in the biotech world. If that is what is going on, we could see a large up front cash payment and/or royalties from a company like $ILMN. And if that is the case, it makes you wonder what the rest of the Exact pipeline is worth. I stand by that Exact could be a $100/share stock one day.
  • c
    chengis khan
    $PACB conversation
    Pacific Biosciences Looking More Interesting Once Again
    PacBio has sold off from its buyout rumor-spiked highs, but the initial interest in the new Sequel system seems solid.Roche's second half launch of the clinical
    seekingalpha.com
  • D
    DougF
    $ILMN conversation
    Well, that is a surprise, an early earnings release before an announced release
  • j
    john.dunlop
    $ILMN conversation
    I agree with Michael... this is a fantastic company with many of the world leaders in genetic analysis... and our population is growing older and will need help beyond poisons and scalpels. I personally have witnessed a friend who was dying of non-small cell lung cancer restored to full health with medication made possible by genetic analysis. Imagine how transformative it is to see your life changed from a nearly immediate death sentence to one where you can have your full enjoyment of life... made possible by taking three small pills twice a day? In my eyes, the employees of Illumina are all heroes!
  • M
    Michael
    $ILMN conversation
    If recent history is a guide, the time to buy is within the first 30 minutes of trading tomorrow. DYODD---because it is possible that ilmm could break below #130 and keep falling for the next few weeks and months. I plan on adding at least 150 shares if it breaches the the $129.50 mark.
  • A
    Anonymous
    Illumina, Inc.
    Pacific Biosciences terminates agreement with Roche. Stock down 40%. Anyone have a guess as to how this might affect Illumina?
  • j
    joe
    $ILMN conversation
    Currently in talks with Roche , hoping for news first quarter
  • A
    Anonymous
    $ILMN conversation
    Interesting article on how the Broad Institute, partnering with Microsoft's Azure platform, reduced it's sequencing time from 28 hours to 4 hours - a greater than 6x increase in throughput. No wonder ILMN's NGS sales were down 25%. They ain't recovering anytime soon. MSFT and AMZN are also working with the National Cancer institure on developing better cancer diagnostics. You are paying a very high price for the hopium of ILMN's future...watch out.
  • M
    Mike
    $ILMN conversation
    ilmm will surge to over $200 by year end. 23&me, a private company of which ilmm owns a stake, and uses illumina sequencing technology is growing exponentially. Consumers, and the general populace, are just now realizing the importance of the genomic revolution. Expect Illumina pps to increase to over $500 within the next 18-24 months.
Usando Yahoo accetti che Yahoo e i suoi partners utilizzino cookies per fini di personalizzazione e altre finalità